We recently published 10 Stocks Crash as AI Glow Fades. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s ...

According to Bender, regulating the use of AI in the pharmaceutical industry may be difficult. “Data, methods and use cases are very diverse and there is no one-size-fits-all approach,” he says.

The U.S. and European Union had first struck a trade agreement in July, but many details were left unresolved at the time.

The AI Revolution is Underway in the Pharmaceutical Industry The global pharmaceutical giant, AstraZeneca (NDQ: AZN), shows promise with their AI implementation strategy in drug development.

With AI as a potent ally, the pharmaceutical industry can offer new hope to patients around the world, turning previously incurable diseases into manageable conditions or even eradicating them ...

Industry-leading pharmaceutical firms are adopting AI to drive value for the future of their enterprise. Several companies in the PPH ETF are currently integrating AI into their operations.

AI-enabled disease modeling, meanwhile, provides a more in-depth understanding of the etiology, transmission and progression of illnesses such as motor neuron disease, cancer and HIV.

AI automation throughout the drug development pipeline is opening up the possibility of faster, cheaper pharmaceuticals. At 82 years old, with an aggressive form of blood cancer that six courses ...

The revenue generated through AI-based solutions in the pharmaceutical industry is projected to rise at a CAGR of 21.94% and reach $2.199 billion by 2022.

This doesn’t mean that big pharma firms aren’t using AI; we’ve heard separately, for example, that Pfizer now has over 150 AI projects underway. But few of them are at the core of drug ...